<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kane Biotech Inc — News on 6ix</title>
<link>https://6ix.com/company/kane-biotech-inc</link>
<description>Latest news and press releases for Kane Biotech Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 22:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kane-biotech-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835f36f78dffbe2df12e592.webp</url>
<title>Kane Biotech Inc</title>
<link>https://6ix.com/company/kane-biotech-inc</link>
</image>
<item>
<title>Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 23 Apr 2026 22:00:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the &#x201C...</description>
</item>
<item>
<title>Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyver-clinical-data-at-symposium-on-advanced-wound-care-sawc-spring-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyver-clinical-data-at-symposium-on-advanced-wound-care-sawc-spring-conference</guid>
<pubDate>Thu, 16 Apr 2026 11:25:00 GMT</pubDate>
<description>>20 year‑old venous leg ulcers show dramatic healing and pain elimination with revyveThermoreversible revyve transforms deep tunneling wound care, delivering 90% wound volume reductionrevyve rapidly normalizes chronic wound pH, driving accelerated healing in weeks WINNIPEG, Manitoba, April 16, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Dr. Miloslav Sailer, External R&D Leader, presented at the Symposium on Advanced Wound</description>
</item>
<item>
<title>Kane Biotech Presents revyve&#xAE; Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyveandxae-clinical-data-at-symposium-on-advanced-wound-care-sawc-spring-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyveandxae-clinical-data-at-symposium-on-advanced-wound-care-sawc-spring-conference</guid>
<pubDate>Thu, 16 Apr 2026 11:25:00 GMT</pubDate>
<description>&gt;20 year&#x2011;old venous leg ulcers show dramatic healing and pain elimination with revyve ...</description>
</item>
<item>
<title>Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-publication-in-frontiers-in-antibiotics-highlighting-advancements-in-treating-antibiotic-tolerant-biofilms</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-publication-in-frontiers-in-antibiotics-highlighting-advancements-in-treating-antibiotic-tolerant-biofilms</guid>
<pubDate>Tue, 17 Mar 2026 11:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms. Key messages of the article as it relates to Kane’s revyve wound gel include: revyve Antimicrobial Wound Gel demonstrated strong activity aga</description>
</item>
<item>
<title>Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-expands-us-commercial-footprint-with-strategic-distribution-partnership-3</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-expands-us-commercial-footprint-with-strategic-distribution-partnership-3</guid>
<pubDate>Tue, 10 Mar 2026 11:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), t...</description>
</item>
<item>
<title>Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-publication-of-revyver-wound-gel-article-in-the-international-wound-journal</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-publication-of-revyver-wound-gel-article-in-the-international-wound-journal</guid>
<pubDate>Fri, 20 Feb 2026 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Phillip Fr</description>
</item>
<item>
<title>Kane Biotech Announces Publication of revyve&#xAE; Wound Gel Article in the International Wound Journal</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-publication-of-revyveandxae-wound-gel-article-in-the-international-wound-journal</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-publication-of-revyveandxae-wound-gel-article-in-the-international-wound-journal</guid>
<pubDate>Fri, 20 Feb 2026 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (&#x201C;Kan...</description>
</item>
<item>
<title>Kane Biotech Expands Commercial Activities in the United States</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-expands-commercial-activities-in-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-expands-commercial-activities-in-the-united-states</guid>
<pubDate>Thu, 19 Feb 2026 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve® Antimicrobial Wound Gel® product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ). US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray These U.S. non-exclusive distribution and sales agreem</description>
</item>
<item>
<title>Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-fda-510-122500426</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-fda-510-122500426</guid>
<pubDate>Tue, 17 Feb 2026 12:25:00 GMT</pubDate>
<description>Company expands ISO 13485/MDSAP Certification to support growing wound care portfolioWINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (“Kane Biotech”. “Kane” or the “Company”) today announces two regulatory milestones that strengthen the Company’s wound care platform and reinforce its commitment to high quality, evidence-based medical device development. Kane has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its revyve® Antimicrobial Skin</description>
</item>
<item>
<title>Kane Biotech Announces FDA 510(k) Clearance for revyve&#xAE; Antimicrobial Skin and Wound Cleanser</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-fda-510k-clearance-for-revyveandxae-antimicrobial-skin-and-wound-cleanser</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-fda-510k-clearance-for-revyveandxae-antimicrobial-skin-and-wound-cleanser</guid>
<pubDate>Tue, 17 Feb 2026 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (&#x201C;Kane ...</description>
</item>
<item>
<title>Kane Biotech Restarts Commercial Activities and Strengthens North American Management</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-restarts-commercial-activities-122500153</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-restarts-commercial-activities-122500153</guid>
<pubDate>Thu, 12 Feb 2026 12:25:00 GMT</pubDate>
<description>Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and CanadaWINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America. US FDA 510(</description>
</item>
<item>
<title>Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-closing-of-private-placement-offering-with-an-insider-of-the-company</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-closing-of-private-placement-offering-with-an-insider-of-the-company</guid>
<pubDate>Thu, 18 Dec 2025 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the &#x201C;...</description>
</item>
<item>
<title>Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-new-data-at-innovations-in-wound-healing-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-new-data-at-innovations-in-wound-healing-annual-meeting</guid>
<pubDate>Wed, 17 Dec 2025 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (&#x201C;Kane...</description>
</item>
<item>
<title>Kane Biotech Receives Health Canada Approval for revyve&#xAE; Antimicrobial Wound Gel Spray</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-receives-health-canada-approval-for-revyveandxae-antimicrobial-wound-gel-spray</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-receives-health-canada-approval-for-revyveandxae-antimicrobial-wound-gel-spray</guid>
<pubDate>Wed, 10 Dec 2025 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (&#x201C;Kane...</description>
</item>
<item>
<title>Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-receives-health-canada-122500089</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-receives-health-canada-122500089</guid>
<pubDate>Wed, 10 Dec 2025 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Health Canada has approved its revyve® Antimicrobial Wound Gel Spray for use in Canada. Health Canada approved revyve Antimicrobial Wound Gel Spray revyve Antimicrobial Wound Gel Spray has been previously cleared under the FDA 510(k) process. This Health Canada approval represents another regulatory milestone for Kane and the Company’s commitment to a</description>
</item>
<item>
<title>Kane Biotech Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-third-quarter-2025-financial-results</guid>
<pubDate>Fri, 28 Nov 2025 12:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (&#x201C;Kane...</description>
</item>
<item>
<title>Kane Biotech Announces New Private Placement Offering</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-new-private-placement-offering</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-announces-new-private-placement-offering</guid>
<pubDate>Thu, 27 Nov 2025 12:25:00 GMT</pubDate>
<description>Not for distribution to U.S. news wire services or dissemination in the United States WINNI...</description>
</item>
<item>
<title>Kane Biotech Presents revyve&#xAE; Data at Diabetic Foot and Southern Region Burn Conferences</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyveandxae-data-at-diabetic-foot-and-southern-region-burn-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyveandxae-data-at-diabetic-foot-and-southern-region-burn-conferences</guid>
<pubDate>Tue, 04 Nov 2025 12:25:00 GMT</pubDate>
<description>Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds 100% diabetic wound c...</description>
</item>
<item>
<title>Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyve-data-122500522</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-presents-revyve-data-122500522</guid>
<pubDate>Tue, 04 Nov 2025 12:25:00 GMT</pubDate>
<description>Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound inf</description>
</item>
<item>
<title>Kane Biotech Completes U.S. FDA 510(k) Submission for revyve&#xAE; Antimicrobial Wound Cleanser</title>
<link>https://6ix.com/company/kane-biotech-inc/news/kane-biotech-completes-us-fda-510k-submission-for-revyveandxae-antimicrobial-wound-cleanser</link>
<guid isPermaLink="true">https://6ix.com/company/kane-biotech-inc/news/kane-biotech-completes-us-fda-510k-submission-for-revyveandxae-antimicrobial-wound-cleanser</guid>
<pubDate>Tue, 16 Sep 2025 21:05:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (&#x201C;Kan...</description>
</item>
</channel>
</rss>